Drug Profile


Alternative Names: 5T4 cancer vaccine; Cancer vaccine - Oxford Biomedica; Modified vaccinia Ankara 5T4; MVA-5T4; MVA-h 5T4; OBA 1 cancer vaccine; OXB-301; Recombinant modified vaccinia Ankara 5T4 vaccine; rV-5T4-VAC; SAR-109659; TroVax

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxford BioMedica
  • Developer Cardiff University; Oxford BioMedica; University College London; Wales Cancer Trials Unit
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Colorectal cancer; Mesothelioma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 01 Nov 2013 Oxford BioMedica initiates enrolment in a phase II TRIOC trial in Ovarian cancer (second-line therapy or greater, early-, mid-stage disease) in United Kingdom(NCT01556841)
  • 29 Jul 2013 Efficacy and adverse events data from a phase II trial in Prostate cancer (combination therapy, hormone refractory) released by Oxford BioMedica
  • 07 Mar 2013 Phase-II clinical trials in Mesothelioma (first-line, combination therapy) in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top